|
|
 Previous Article | Table of Contents | Next Article 
Lipoprotein(a) Is a Potent Chemoattractant for Human Peripheral Monocytes
Tatjana Syrovets,
Joëlle Thillet,
M. John Chapman, and
Thomas Simmet
From the Department of Pharmacology and Toxicology, Ruhr University, Bochum, Germany; and Institut National de la Santé et de la Recherche Medicale (INSERM) Unité 321, Paris, France.
We have previously reported that the serine protease plasmin triggers chemotaxis in human peripheral monocytes, but not in polymorphonuclear leukocyte. We now show that the structurally related lipoprotein(a) (Lp[a]) as well as recombinant apolipoprotein(a) (apo[a]) trigger chemotactic responses in human monocytes equipotent to that observed with the standard chemoattractant FMLP. The chemotactic effects of Lp(a) and FMLP were additive. Low density lipoprotein (LDL) did not elicit any significant chemotactic response nor did it interfere with that triggered by Lp(a). As assessed by checkerboard analysis, Lp(a)-mediated monocyte locomotion was a true chemotaxis. Both plasminogen as well as catalytically inactivated plasmin inhibited monocyte migration elicited by Lp(a), suggesting binding of Lp(a) to plasminogen binding sites. Lp(a)-mediated signaling proceeds through a pertussis toxin-sensitive guanosine triphosphate (GTP)-binding protein and activation of protein kinase C as implicated by the effects of 1-O-hexadecyl-2-O-methyl-rac-glycerol and chelerythrine. Lp(a) induced generation of guanosine 3',5'-cyclic monophosphate (cGMP), apparently crucial for the Lp(a)-mediated chemotaxis, because an inhibitor of soluble guanylyl cyclase, LY83583, reduced both the Lp(a)-induced cGMP formation as well as the monocyte migration. The latter effect of LY83583 was antagonized by the stable cGMP analog 8-pCPT-cGMP. The data indicate that Lp(a) triggers chemotaxis in human monocytes by way of a cGMP-dependent mechanism. Our findings may have important implications for the atherogenesis associated with elevated levels of Lp(a).
Blood, Vol. 90 No. 5 (September 1), 1997:
pp. 2027-2036
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. B. Lanktree, C. Rajakumar, J. H. Brunt, M. L. Koschinsky, P. W. Connelly, and R. A. Hegele
Determination of lipoprotein(a) kringle repeat number from genomic DNA: copy number variation genotyping using qPCR
J. Lipid Res.,
April 1, 2009;
50(4):
768 - 772.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Hoover-Plow, E. Hart, Y. Gong, A. Shchurin, and T. Schneeman
A Physiological Function for Apolipoprotein(a): A Natural Regulator of the Inflammatory Response
Experimental Biology and Medicine,
January 1, 2009;
234(1):
28 - 34.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Tsimikas, L. D. Tsironis, and A. D. Tselepis
New Insights Into the Role of Lipoprotein(a)-Associated Lipoprotein-Associated Phospholipase A2 in Atherosclerosis and Cardiovascular Disease
Arterioscler Thromb Vasc Biol,
October 1, 2007;
27(10):
2094 - 2099.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Laumonnier, T. Syrovets, L. Burysek, and T. Simmet
Identification of the annexin A2 heterotetramer as a receptor for the plasmin-induced signaling in human peripheral monocytes
Blood,
April 15, 2006;
107(8):
3342 - 3349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. D. Wu, L. Berglund, C. Dimayuga, J. Jones, R. R. Sciacca, M. R. Di Tullio, and S. Homma
High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort
J. Am. Coll. Cardiol.,
May 19, 2004;
43(10):
1828 - 1833.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. WAHN, V. DANIEL, F. KRONENBERG, G. OPELZ, D. V. MICHALK, and U. QUERFELD
Impact of Apolipoprotein(a) Phenotypes on Long-Term Renal Transplant Survival
J. Am. Soc. Nephrol.,
May 1, 2001;
12(5):
1052 - 1058.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
Y.-S. Bae, H. Bae, Y. Kim, T. G. Lee, P.-G. Suh, and S. H. Ryu
Identification of novel chemoattractant peptides for human leukocytes
Blood,
May 1, 2001;
97(9):
2854 - 2862.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Shi, M. E. Haberland, M.-L. Jien, D. M. Shih, and A. J. Lusis
Endothelial Responses to Oxidized Lipoproteins Determine Genetic Susceptibility to Atherosclerosis in Mice
Circulation,
July 4, 2000;
102(1):
75 - 81.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Lippi and G. Guidi
Lipoprotein(a): from ancestral benefit to modern pathogen?
QJM,
February 1, 2000;
93(2):
75 - 84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Bdeir, W. Cane, G. Canziani, I. Chaiken, J. Weisel, M. L. Koschinsky, R. M. Lawn, P. G. Bannerman, B. S. Sachais, A. Kuo, et al.
Defensin Promotes the Binding of Lipoprotein(a) to Vascular Matrix
Blood,
September 15, 1999;
94(6):
2007 - 2019.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Kronenberg, M. F. Kronenberg, S. Kiechl, E. Trenkwalder, P. Santer, F. Oberhollenzer, G. Egger, G. Utermann, and J. Willeit
Role of Lipoprotein(a) and Apolipoprotein(a) Phenotype in Atherogenesis : Prospective Results From the Bruneck Study
Circulation,
September 14, 1999;
100(11):
1154 - 1160.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Notsu, T. Nabika, H.-Y. Park, J. Masuda, and S. Kobayashi
Evaluation of Genetic Risk Factors for Silent Brain Infarction
Stroke,
September 1, 1999;
30(9):
1881 - 1886.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
